| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911234 | Lung Cancer | 2013 | 8 Pages |
Abstract
Radical treatment of selected NSCLC patients presenting with 1-3 synchronous metastases can result in favorable 2-year survivals. Favorable outcomes were associated with intra-thoracic disease status: patients with small radiotherapy treatment volumes or resected disease had the best OS. Future prospective clinical trials, ideally randomized, should evaluate radical treatment strategies in such patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gwendolyn H.M.J. Griffioen, Daniel Toguri, Max Dahele, Andrew Warner, Patricia F. de Haan, George B. Rodrigues, Ben J. Slotman, Brian P. Yaremko, Suresh Senan, David A. Palma,